ICI-199441 HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 562557

CAS#: 115199-84-3 (HCl)

Description: ICI-199441 HCl is a highly potent κ agonist.


Chemical Structure

img
ICI-199441 HCl
CAS# 115199-84-3 (HCl)

Theoretical Analysis

MedKoo Cat#: 562557
Name: ICI-199441 HCl
CAS#: 115199-84-3 (HCl)
Chemical Formula: C21H25Cl3N2O
Exact Mass:
Molecular Weight: 427.79
Elemental Analysis: C, 58.96; H, 5.89; Cl, 24.86; N, 6.55; O, 3.74

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 116508-24-8 (free base)   115199-84-3 (HCl)   136328-89-7 (R-isomer)   159531-32-5 (racemic)    

Synonym: ICI-199441 HCl; ICI 199441 HCl; ICI199441 HCl; ICI-199441 Hydrochloride; ICI 199441 Hydrochloride; ICI199441 Hydrochloride;

IUPAC/Chemical Name: 2-(3,4-Dichlorophenyl)-N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl]acetamide hydrochloride

InChi Key: VFLWVWZSDBTGQJ-VEIFNGETSA-N

InChi Code: InChI=1S/C21H24Cl2N2O.ClH/c1-24(21(26)14-16-9-10-18(22)19(23)13-16)20(15-25-11-5-6-12-25)17-7-3-2-4-8-17;/h2-4,7-10,13,20H,5-6,11-12,14-15H2,1H3;1H/t20-;/m1./s1

SMILES Code: O=C(N(C)[C@@H](C1=CC=CC=C1)CN2CCCC2)CC3=CC=C(Cl)C(Cl)=C3.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 427.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Jacobs BA, Pando MM, Jennings E, Chavera TA, Clarke WP, Berg KA. Allosterism within δ Opioid-κ Opioid Receptor Heteromers in Peripheral Sensory Neurons: Regulation of κ Opioid Agonist Efficacy. Mol Pharmacol. 2018 Apr;93(4):376-386. doi: 10.1124/mol.117.109975. Epub 2018 Feb 7. PubMed PMID: 29436492; PubMed Central PMCID: PMC5832326.

2: Tsibulnikov SY, Maslov LN, Mukhomedzyanov AV, Krylatov AV, Tsibulnikova MR, Lishmanov YB. Prospects of Using of κ-Opioid Receptor Agonists U-50,488 and ICI 199,441 for Improving Heart Resistance to Ischemia/Reperfusion. Bull Exp Biol Med. 2015 Oct;159(6):718-21. doi: 10.1007/s10517-015-3057-8. Epub 2015 Oct 31. PubMed PMID: 26519268.

3: Nascimento AI, Ferreira HS, Saraiva RM, Almeida TS, Fregoneze JB. Central kappa opioid receptors modulate salt appetite in rats. Physiol Behav. 2012 Jun 25;106(4):506-14. doi: 10.1016/j.physbeh.2012.03.028. Epub 2012 Mar 29. PubMed PMID: 22484111.

4: Su X, Castle NA, Antonio B, Roeloffs R, Thomas JB, Krafte DS, Chapman ML. The effect of kappa-opioid receptor agonists on tetrodotoxin-resistant sodium channels in primary sensory neurons. Anesth Analg. 2009 Aug;109(2):632-40. doi: 10.1213/ane.0b013e3181a909a4. PubMed PMID: 19608841.

5: Zhang J, Liu G, Tang Y. Chemical function-based pharmacophore generation of selective kappa-opioid receptor agonists by catalyst and phase. J Mol Model. 2009 Sep;15(9):1027-41. doi: 10.1007/s00894-008-0418-5. Epub 2009 Feb 11. PubMed PMID: 19205759.

6: Tao YM, Li QL, Zhang CF, Xu XJ, Chen J, Ju YW, Chi ZQ, Long YQ, Liu JG. LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential. Eur J Pharmacol. 2008 Apr 28;584(2-3):306-11. doi: 10.1016/j.ejphar.2008.02.028. Epub 2008 Feb 19. PubMed PMID: 18353307.

7: Page AJ, O'Donnell TA, Blackshaw LA. Opioid modulation of ferret vagal afferent mechanosensitivity. Am J Physiol Gastrointest Liver Physiol. 2008 Apr;294(4):G963-70. doi: 10.1152/ajpgi.00562.2007. Epub 2008 Feb 7. PubMed PMID: 18258789.

8: Terner JM, Lomas LM, Lewis JW, Husbands SM, Picker MJ. Effects of the long-lasting kappa opioid 2-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1-(3-isothiocyanatophenyl)-2-(1-pyrrolidi nyl) ethyl] acetamide in a drug discrimination and warm water tail-withdrawal procedure. Behav Pharmacol. 2005 Dec;16(8):665-70. PubMed PMID: 16286819.

9: Narita M, Kaneko C, Miyoshi K, Nagumo Y, Kuzumaki N, Nakajima M, Nanjo K, Matsuzawa K, Yamazaki M, Suzuki T. Chronic pain induces anxiety with concomitant changes in opioidergic function in the amygdala. Neuropsychopharmacology. 2006 Apr;31(4):739-50. PubMed PMID: 16123756.

10: Le Bourdonnec B, Ajello CW, Seida PR, Susnow RG, Cassel JA, Belanger S, Stabley GJ, DeHaven RN, DeHaven-Hudkins DL, Dolle RE. Arylacetamide kappa opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity. Bioorg Med Chem Lett. 2005 May 16;15(10):2647-52. PubMed PMID: 15863335.

11: Daniels DJ, Kulkarni A, Xie Z, Bhushan RG, Portoghese PS. A bivalent ligand (KDAN-18) containing delta-antagonist and kappa-agonist pharmacophores bridges delta2 and kappa1 opioid receptor phenotypes. J Med Chem. 2005 Mar 24;48(6):1713-6. PubMed PMID: 15771416.

12: Tuthill PA, Seida PR, Barker W, Cassel JA, Belanger S, DeHaven RN, Koblish M, Gottshall SL, Little PJ, DeHaven-Hudkins DL, Dolle RE. Azepinone as a conformational constraint in the design of kappa-opioid receptor agonists. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5693-7. PubMed PMID: 15482950.

13: Mori T, Nomura M, Yoshizawa K, Nagase H, Narita M, Suzuki T. Differential properties between TRK-820 and U-50,488H on the discriminative stimulus effects in rats. Life Sci. 2004 Oct 1;75(20):2473-82. PubMed PMID: 15350822.

14: Suzuki T, Izumimoto N, Takezawa Y, Fujimura M, Togashi Y, Nagase H, Tanaka T, Endoh T. Effect of repeated administration of TRK-820, a kappa-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions. Brain Res. 2004 Jan 9;995(2):167-75. PubMed PMID: 14672806.

15: Nakae Y, Fujita S, Namiki A. Modulation of myofilament Ca2+ densitivity by delta- and kappa-opioid agonists in intact guinea pig hearts. Anesth Analg. 2003 Mar;96(3):733-9, table of contents. PubMed PMID: 12598254.

16: Kumar V, Marella MA, Cortes-Burgos L, Chang AC, Cassel JA, Daubert JD, DeHaven RN, DeHaven-Hudkins DL, Gottshall SL, Mansson E, Maycock AL. Arylacetamides as peripherally restricted kappa opioid receptor agonists. Bioorg Med Chem Lett. 2000 Nov 20;10(22):2567-70. PubMed PMID: 11086731.

17: Perez JM, Wilhelm EJ, Sucholeiki I. The use of power ultrasound coupled with magnetic separation for the solid phase synthesis of compound libraries. Bioorg Med Chem Lett. 2000 Jan 17;10(2):171-4. PubMed PMID: 10673104.

18: Endoh T, Tajima A, Suzuki T, Kamei J, Narita M, Tseng L, Nagase H. Characterization of the antinociceptive effects of TRK-820 in the rat. Eur J Pharmacol. 2000 Jan 10;387(2):133-40. PubMed PMID: 10650153.

19: Chang AC, Cowan A, Takemori AE, Portoghese PS. Aspartic acid conjugates of 2-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1(3-aminophenyl)-2-(1-pyrrolidi nyl) ethyl]acetamide: kappa opioid receptor agonists with limited access to the central nervous system. J Med Chem. 1996 Oct 25;39(22):4478-82. PubMed PMID: 8893842.

20: Costello GF, Main BG, Barlow JJ, Carroll JA, Shaw JS. A novel series of potent and selective agonists at the opioid kappa-receptor. Eur J Pharmacol. 1988 Jul 14;151(3):475-8. PubMed PMID: 2850924.